Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease

Experimental Neurology

Volumn 300, Issue , 2018, Pages 179-187

  Harms, Ashley S ^a   Thome, Aaron D ^a   Yan, Zhaoqi ^b   Schonhoff, Aubrey M ^a   Williams, Gregory P ^a   Li, Xinru ^a   Liu, Yudong ^b   Qin, Hongwei ^b   Benveniste, Etty N ^b   Standaert, David G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

C C chemokine receptor type 2 (CCR2); Fractalkine receptor (CX3CR1) Major histocompatibility complex II (MHCII); Microglia; Monocytes; Parkinson disease (PD); syn (alpha synuclein)

Indexed keywords

ALPHA SYNUCLEIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; DESMUSLIN; INTERMEDIATE FILAMENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MONOCYTE; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; 129 MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; INFLAMMATION; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERMEDIATE FILAMENT PROTEINS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; NERVE DEGENERATION; PARKINSON DISEASE, SECONDARY;

EID: 85034624068     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2017.11.010     Document Type: Article

References (65)

1. Ajami, B. et al., Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14:9 (2011), 1142–1149.
2. Allen Reish, H.E., Standaert, D.G., Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J. Parkinsons Dis. 5:1 (2015), 1–19.
3. Appel, S.H., Inflammation in Parkinson's disease: cause or consequence?. Mov. Disord. 27:9 (2012), 1075–1077.
4. Bennett, M.L. et al., New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. U. S. A. 113:12 (2016), E1738–46.
5. Blum-Degen, D. et al., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202:1–2 (1995), 17–20.
6. Brochard, V. et al., Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119:1 (2009), 182–192.
7. Butovsky, O. et al., Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 122:9 (2012), 3063–3087.
8. Butovsky, O. et al., Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci. 17:1 (2014), 131–143.
9. Cao, S., Theodore, S., Standaert, D.G., Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol. Neurodegener., 5, 2010, 42.
10. Cao, S., Standaert, D.G., Harms, A.S., The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J. Neuroinflammation, 9(1), 2012, 259.
11. Columba-Cabezas, S. et al., Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 130:1–2 (2002), 10–21.
12. Daeron, M., Fc receptor biology. Annu. Rev. Immunol. 15 (1997), 203–234.
13. Fife, B.T. et al., CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192:6 (2000), 899–905.
14. Funk, N. et al., Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease. Mov. Disord. 28:3 (2013), 392–395.
15. Gao, H.M. et al., Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28:30 (2008), 7687–7698.
16. Gao, X. et al., Use of ibuprofen and risk of Parkinson disease. Neurology 76:10 (2011), 863–869.
17. Gaupp, S. et al., Experimental autoimmune encephalomyelitis (EAE) in CCR2(−/−) mice: susceptibility in multiple strains. Am. J. Pathol. 162:1 (2003), 139–150.
18. Grozdanov, V. et al., Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol. 128:5 (2014), 651–663.
19. Hamza, T.H. et al., Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42:9 (2010), 781–785.
20. Harms, A.S. et al., MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 33:23 (2013), 9592–9600.
21. Hirsch, E.C., Hunot, S., Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 8:4 (2009), 382–397.
22. Hirsch, E.C., Vyas, S., Hunot, S., Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord. 18:Suppl. 1 (2012), S210–2.
23. Houlden, H., Singleton, A.B., The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124:3 (2012), 325–338.
24. Izikson, L. et al., Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192:7 (2000), 1075–1080.
25. Jung, S. et al., Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20:11 (2000), 4106–4114.
26. Langston, J.W. et al., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46:4 (1999), 598–605.
27. Lim, S. et al., Neuroinflammation in Synucleinopathies. Brain Pathol. 26:3 (2016), 404–409.
28. Luk, K.C. et al., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:6109 (2012), 949–953.
29. Mahad, D. et al., Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129:Pt 1 (2006), 212–223.
30. McGeer, P.L. et al., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:8 (1988), 1285–1291.
31. Mizutani, M. et al., The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J. Immunol. 188:1 (2012), 29–36.
32. Moehle, M.S., West, A.B., M1 and M2 immune activation in Parkinson's Disease: foe and ally?. Neuroscience 302 (2015), 59–73.
33. Mogi, M. et al., Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:2 (1994), 147–150.
34. Mogi, M. et al., Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165:1–2 (1994), 208–210.
35. Mount, M.P. et al., Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 27:12 (2007), 3328–3337.
36. Orr, C.F. et al., A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128:Pt 11 (2005), 2665–2674.
37. Polymeropoulos, M.H., Autosomal dominant Parkinson's disease and alpha-synuclein. Ann. Neurol. 44:3 Suppl 1 (1998), S63–4.
38. Polymeropoulos, M.H. et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:5321 (1997), 2045–2047.
39. Prinz, M. et al., Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 14:10 (2011), 1227–1235.
40. Qin, H. et al., Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. U. S. A. 109:13 (2012), 5004–5009.
41. Raj, T. et al., Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344:6183 (2014), 519–523.
42. Ransohoff, R.M., Microglia and monocytes: 'tis plain the twain meet in the brain. Nat. Neurosci. 14:9 (2011), 1098–1100.
43. Ransohoff, R.M., Cardona, A.E., The myeloid cells of the central nervous system parenchyma. Nature 468:7321 (2010), 253–262.
44. Reale, M. et al., Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 23:1 (2009), 55–63.
45. Reynolds, A.D. et al., Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 104:6 (2008), 1504–1525.
46. Reynolds, A.D. et al., Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4 + T cell subsets. J. Immunol. 182:7 (2009), 4137–4149.
47. Ross, O.A. et al., Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 63:6 (2008), 743–750.
48. Saederup, N. et al., Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One, 5(10), 2010, e13693.
49. Saijo, K., Glass, C.K., Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 11:11 (2011), 775–787.
50. Sanchez-Guajardo, V. et al., Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One, 5(1), 2010, e8784.
51. Saunders, J.A. et al., CD4 + regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J. NeuroImmune Pharmacol. 7:4 (2012), 927–938.
52. Schmid, C.D. et al., Differential gene expression in LPS/IFNgamma activated microglia and macrophages: in vitro versus in vivo. J. Neurochem. 109:Suppl. 1 (2009), 117–125.
53. Simon-Sanchez, J. et al., Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41:12 (2009), 1308–1312.
54. Soldner, F. et al., Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. Nature 533:7601 (2016), 95–99.
55. St Martin, J.L. et al., Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 100:6 (2007), 1449–1457.
56. Tansey, M.G., Goldberg, M.S., Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37:3 (2010), 510–518.
57. Theodore, S. et al., Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67:12 (2008), 1149–1158.
58. Thome, A.D., Standaert, D.G., Harms, A.S., Fractalkine signaling regulates the inflammatory response in an alpha-Synuclein model of Parkinson disease. PLoS One, 10(10), 2015, e0140566.
59. Thome, A.D. et al., microRNA-155 regulates alpha-Synuclein-induced inflammatory responses in models of Parkinson disease. J. Neurosci. 36:8 (2016), 2383–2390.
60. Volpicelli-Daley, L.A. et al., Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:1 (2011), 57–71.
61. Volpicelli-Daley, L.A. et al., How can rAAV-alpha-synuclein and the fibril alpha-synuclein models advance our understanding of Parkinson disease?. J. Neurochem. 139:Supplemental 1 (2016), 131–155.
62. Watson, M.B., Lee, S.K., Richter, F., Masliah, E., Chesselet, M.-F., Regionally Specific Microglial Activation Precedes Neuropathology and Peripheral Immune Response in Mice Over-Expressing Wildtype Alpha Synuclein. 2011, 2011, Society for Neuroscience, Washington, D.C.
63. Watson, M.B. et al., Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp. Neurol. 237:2 (2012), 318–334.
64. Whitton, P.S., Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150:8 (2007), 963–976.
65. Yamasaki, R. et al., Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211:8 (2014), 1533–1549.